/
Neurology
Cerebral Palsy
21
Pipeline Programs↗
84
Active Trials↗
27
Companies Involved↗
Cerebral Palsy is an emerging landscape with 21 programs across 27 companies. The most active players are Neurocrine Biosciences. 2 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical15
Approved
No programs
Analysis
Modality Breakdown
94%
Small molecule
17 of 18 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 18 classified programs, each share of the total. Modality classified for 100% of 21 pipeline programs.
Analysis
Trial Status
213
clinical trials
Completed92 · 43%
Not yet recruiting36 · 17%
Recruiting26 · 12%
Unknown status18 · 8%
Active, not recruiting17 · 8%
Terminated11 · 5%
Other13 · 6%
Clinical Trials
Trial Activity
213 trials
Dorsal Root Electrical Stimulation to Suppress Spastic Muscle Activation in Children With Cerebral Palsy
Recruiting·—·Preclinical·NCT07715006·15 enrolled
Page 1 of 15
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)